North America Exosome Therapeutic Market - Industry Trends and Forecast to 2026

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF NORTH AMERICA EXOSOME THERAPEUTIC MARKET

1.4 LIMITATIONS

1.5 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 CURRENCY AND PRICING

2.5 DBMR TRIPOD DATA VALIDATION MODEL

2.6 MULTIVARIATE MODELLING

2.7 PRODUCTS LIFELINE CURVE

2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.9 SECONDARY SOURCES

2.10 ASSUMPTIONS

3 MARKET OVERVIEW

3.1 DRIVERS

3.1.1 INCREASING PREVALENCE OF LYME DISEASE, CHRONIC INFLAMMATION, AUTOIMMUNE DISEASE AND OTHER CHRONIC DEGENERATIVE DISEASES

3.1.2 INCREASING DEMAND FOR ANTI-AGING THERAPY’S

3.2 RESTRAINT

3.2.1 UNMET MEDICAL NEEDS

3.3 OPPORTUNITIES

3.3.1 PROGRESSING THERAPEUTIC VALUE OF EXOSOME

3.3.2 AVAILABILITY OF VARIOUS EXOSOME ISOLATION AND PURIFICATION TECHNIQUES

3.3.3 TECHNOLOGICAL ADVANCEMENTS IN EXOSOME

3.3.4 STRATEGIC RESEARCH INITIATIVES BY MARKET PLAYERS

3.3.5 RISING HEALTHCARE INFRASTRUCTURE

3.4 CHALLENGE

3.4.1 LACK OF SKILLED PROFESSIONAL’S REQUIRED FOR THE ISOLATION OF EXOSOME

4 EXECUTIVE SUMMARY

5 PREMIUM INSIGHTS

6 PIPELINE

7 NORTH AMERICA EXOSOME THERAPEUTIC MARKET, BY TYPE

7.1 OVERVIEW

7.2 HYBRID EXOSOMES

7.3 NATURAL EXOSOMES

7.3.1 AUTOLOGOUS EXOSOMES

7.3.2 EXOGENOUS EXOSOMES

8 NORTH AMERICA EXOSOME THERAPEUTIC MARKET, BY SOURCE

8.1 OVERVIEW

8.2 MESENCHYMAL STEM CELLS

8.3 DENDRITIC CELLS

8.4 BLOOD

8.4.1 B LYMPHOCYTES

8.4.2 OTHERS

8.5 BODY FLUIDS

8.5.1 SYNOVIAL FLUID

8.5.2 AMNIOTIC FLUID

8.5.3 SEMEN

8.5.4 OTHERS

8.6 MILK

8.7 SALIVA

8.8 URINE

8.9 OTHERS

9 NORTH AMERICA EXOSOME THERAPEUTIC MARKET, BY THERAPY

9.1 OVERVIEW

9.2 CHEMOTHERAPY

9.3 IMMUNOTHERAPY

9.4 GENE THERAPY

10 NORTH AMERICA EXOSOME THERAPEUTIC MARKET, BY TRANSPORTING CAPACITY

10.1 OVERVIEW

10.2 BIO MACROMOLECULES

10.2.1 NUCLEIC ACIDS

10.2.2 PEPTIDES

10.2.3 PROTEINS

10.3 SMALL MOLECULES

11 NORTH AMERICA EXOSOME THERAPEUTIC MARKET, BY APPLICATION

11.1 OVERVIEW

11.2 ONCOLOGY

11.2.1 NON-SMALL CELL LUNG CANCER

11.2.2 BREAST CANCER

11.2.3 GASTRIC CANCER

11.2.4 HEAD AND NECK CANCER

11.2.5 OTHERS

11.3 CARDIAC DISORDERS

11.4 METABOLIC DISORDERS

11.5 NEUROLOGY

11.5.1 PARKINSON'S DISEASE

11.5.2 ALZHEIMER'S DISEASE

11.5.3 OTHERS

11.6 BLOOD DISORDERS

11.7 GYNECOLOGY DISORDERS

11.8 INFLAMMATORY DISORDERS

11.9 ORGAN TRANSPLANTATION

11.10 OTHERS

12 NORTH AMERICA EXOSOME THERAPEUTIC MARKET, BY ROUTE OF ADMINISTRATION

12.1 OVERVIEW

12.2 PARENTERAL

12.3 ORAL

13 NORTH AMERICA EXOSOME THERAPEUTIC MARKET, BY END USER

13.1 OVERVIEW

13.2 HOSPITALS

13.3 RESEARCH & ACADEMIC INSTITUTES

13.4 DIAGNOSTIC CENTERS

14 NORTH AMERICA EXOSOME THERAPEUTIC MARKET, BY GEOGRAPHY

14.1 NORTH AMERICA

14.1.1 U.S.

14.1.2 MEXICO

15 NORTH AMERICA EXOSOME THERAPEUTIC MARKET, COMPANY LANDSCAPE

15.1 COMPANY SHARE ANALYSIS: NORTH AMERICA

16 COMPANY PROFILE

16.1 STEM CELLS GROUP

16.1.1 COMPANY SNAPSHOT

16.1.2 PRODUCT PORTFOLIO

16.1.3 RECENT DEVELOPMENT

16.2 EXOCOBIO

16.2.1 COMPANY SNAPSHOT

16.2.2 PRODUCT PORTFOLIO

16.2.3 RECENT DEVELOPMENT

16.3 AEGLE THERPEUTICS

16.3.1 COMPANY SNAPSHOT

16.3.2 PIPELINE PORTFOLIO

16.4 AVALON GLOBOCARE CORP.

16.4.1 COMPANY SNAPSHOT

16.4.2 REVENUE ANALYSIS

16.4.3 PIPELINE PORTFOLIO

16.4.4 RECENT DEVELOPMENT

16.5 BOEHRINGER INGELHEIM INTERNATIONAL GMBH

16.5.1 COMPANY SNAPSHOT

16.5.2 REVENUE ANALYSIS

16.5.3 PRODUCT PORTFOLIO

16.5.4 RECENT DEVELOPMENT

16.6 CAPRICOR THERAPEUTICS

16.6.1 COMPANY SNAPSHOT

16.6.2 PRODUCT PORTFOLIO

16.6.3 RECENT DEVELOPMENTS

16.7 CODIAK BIOSCIENCES

16.7.1 COMPANY SNAPSHOT

16.7.2 PIPELINE PORTFOLIO

16.7.3 RECENT DEVELOPMENTS

16.8 CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.

16.8.1 COMPANY SNAPSHOT

16.8.2 REVENUE ANALYSIS

16.8.3 PIPELINE PORTFOLIO

16.8.4 RECENT DEVELOPMENT

16.9 EXOPHARM

16.9.1 COMPANY SNAPSHOT

16.9.2 REVENUE ANALYSIS

16.9.3 PIPELINE PORTFOLIO

16.9.4 RECENT DEVELOPMENT

16.10 EVOX THERAPEUTICS

16.10.1 COMPANY SNAPSHOT

16.10.2 PIPELINE PORTFOLIO

16.10.3 RECENT DEVELOPMENTS

16.11 JAZZ PHARMACEUTICALS, INC.

16.11.1 COMPANY SNAPSHOT

16.11.2 REVENUE ANALYSIS

16.11.3 PRODUCT PORTFOLIO

16.11.4 RECENT DEVELOPMENT

16.12 RENEURON GROUP PLC

16.12.1 COMPANY SNAPSHOT

16.12.2 REVENUE ANALYSIS

16.12.3 PRODUCT PORTFOLIO

16.12.4 RECENT DEVELOPMENT

16.13 UNITED THERAPEUTICS CORPORATION

16.13.1 COMPANY SNAPSHOT

16.13.2 REVENUE ANALYSIS

16.13.3 PRODUCT PORTFOLIO

16.13.4 RECENT DEVELOPMENT

17 QUESTIONNAIRE

18 RELATED REPORTS

UU

TABLE 1 EXOSOMES USED AS DRUG/GENE DELIVERY CARRIERS.

TABLE 2 COMPARISON OF CONVENTIONAL AND MICROFLUIDICS-BASEDEXOSOME ISOLATION TECHNIQUES

TABLE 3 STRATEGIC RESEARCH INITIATIVES BY MARKET PLAYERS

TABLE 4 HEALTHCARE EXPENDITURE IN ASIA-PACIFIC

TABLE 5 NORTH AMERICA EXOSOME THERAPEUTIC MARKET, BY TYPE, 2017-2026 (USD MILLION)

TABLE 6 NORTH AMERICA HYBRID EXOSOMES IN EXOSOME THERAPEUTIC MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 7 NORTH AMERICA NATURAL EXOSOMES IN EXOSOME THERAPEUTIC MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 8 NORTH AMERICA NATURAL EXOSOMES IN EXOSOME THERAPEUTIC MARKET, BY TYPE, 2017-2026 (USD MILLION)

TABLE 9 NORTH AMERICA EXOSOME THERAPEUTIC MARKET, BY SOURCE, 2017-2026 (USD MILLION)

TABLE 10 NORTH AMERICA MESENCHYMAL STEM CELLS IN EXOSOME THERAPEUTIC MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 11 NORTH AMERICA DENDRITIC CELLS IN EXOSOME THERAPEUTIC MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 12 NORTH AMERICA BLOOD IN EXOSOME THERAPEUTIC MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 13 NORTH AMERICA BLOOD IN EXOSOME THERAPEUTIC MARKET, BY SOURCE, 2017-2026 (USD MILLION)

TABLE 14 NORTH AMERICA BODY FLUIDS IN EXOSOME THERAPEUTIC MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 15 NORTH AMERICA BODY FLUIDS IN EXOSOME THERAPEUTIC MARKET, BY SOURCE, 2017-2026 (USD MILLION)

TABLE 16 NORTH AMERICA MILK IN EXOSOME THERAPEUTIC MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 17 NORTH AMERICA SALIVA IN EXOSOME THERAPEUTIC MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 18 NORTH AMERICA URINE IN EXOSOME THERAPEUTIC MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 19 NORTH AMERICA OTHERS IN EXOSOME THERAPEUTIC MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 20 NORTH AMERICA EXOSOME THERAPEUTIC MARKET, BY THERAPY, 2017-2026 (USD MILLION)

TABLE 21 NORTH AMERICA CHEMOTHERAPY IN EXOSOME THERAPEUTIC MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 22 NORTH AMERICA IMMUNOTHERAPY IN EXOSOME THERAPEUTIC MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 23 NORTH AMERICA GENE THERAPY IN EXOSOME THERAPEUTIC MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 24 NORTH AMERICA EXOSOME THERAPEUTIC MARKET, BY TRANSPORTING CAPACITY, 2017-2026 (USD MILLION)

TABLE 25 NORTH AMERICA BIO MACROMOLECULES IN EXOSOME THERAPEUTIC MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 26 NORTH AMERICA BIO MACROMOLECULES IN EXOSOME THERAPEUTIC MARKET, BY SOURCE, 2017-2026 (USD MILLION)

TABLE 27 NORTH AMERICA SMALL MOLECULES IN EXOSOME THERAPEUTIC MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 28 NORTH AMERICA EXOSOME THERAPEUTIC MARKET, BY APPLICATION, 2017-2026 (USD MILLION)

TABLE 29 NORTH AMERICA ONCOLOGY IN EXOSOME THERAPEUTIC MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 30 NORTH AMERICA ONCOLOGY IN EXOSOME THERAPEUTIC MARKET, BY APPLICATION, 2017-2026 (USD MILLION)

TABLE 31 NORTH AMERICA CARDIAC DISORDERS IN EXOSOME THERAPEUTIC MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 32 NORTH AMERICA METABOLIC DISORDERS IN EXOSOME THERAPEUTIC MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 33 NORTH AMERICA NEUROLOGY IN EXOSOME THERAPEUTIC MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 34 NORTH AMERICA NEUROLOGY IN EXOSOME THERAPEUTIC MARKET, BY APPLICATION, 2017-2026 (USD MILLION)

TABLE 35 NORTH AMERICA BLOOD DISORDERS IN EXOSOME THERAPEUTIC MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 36 NORTH AMERICA GYNECOLOGY DISORDERS IN EXOSOME THERAPEUTIC MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 37 NORTH AMERICA INFLAMMATORY DISORDERS IN EXOSOME THERAPEUTIC MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 38 NORTH AMERICA ORGAN TRANSPLANTATION IN EXOSOME THERAPEUTIC MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 39 NORTH AMERICA OTHERS IN EXOSOME THERAPEUTIC MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 40 NORTH AMERICA EXOSOME THERAPEUTIC MARKET, BY ROUTE OF ADMINISTRATION, 2017-2026 (USD MILLION)

TABLE 41 NORTH AMERICA PARENTERAL IN EXOSOME THERAPEUTIC MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 42 NORTH AMERICA ORAL IN EXOSOME THERAPEUTIC MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 43 NORTH AMERICA EXOSOME THERAPEUTIC MARKET, BY END USER, 2017-2026 (USD MILLION)

TABLE 44 NORTH AMERICA HOSPITALS IN EXOSOME THERAPEUTIC MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 45 NORTH AMERICA RESEARCH & ACADEMIC INSTITUTES IN EXOSOME THERAPEUTIC MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 46 NORTH AMERICA DIAGNOSTIC CENTERS IN EXOSOME THERAPEUTIC MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 47 NORTH AMERICA EXOSOME THERAPEUTIC MARKET, BY COUNTRY 2017-2026 (USD MILLION)

TABLE 48 NORTH AMERICA EXOSOME THERAPEUTIC MARKET, BY TYPE, 2017-2026 (USD MILLION)

TABLE 49 NORTH AMERICA NATURAL EXOSOMES IN EXOSOME THERAPEUTIC MARKET, BY TYPE, 2017-2026 (USD MILLION)

TABLE 50 NORTH AMERICA EXOSOME THERAPEUTIC MARKET, BY SOURCE, 2017-2026 (USD MILLION)

TABLE 51 NORTH AMERICA BLOOD IN EXOSOME THERAPEUTIC MARKET, BY SOURCE, 2017-2026 (USD MILLION)

TABLE 52 NORTH AMERICA BODY FLUIDS IN EXOSOME THERAPEUTIC MARKET, BY SOURCE, 2017-2026 (USD MILLION)

TABLE 53 NORTH AMERICA EXOSOME THERAPEUTIC MARKET, BY THERAPY, 2017-2026 (USD MILLION)

TABLE 54 NORTH AMERICA EXOSOME THERAPEUTIC MARKET, BY TRANSPORTING CAPACITY, 2017-2026 (USD MILLION)

TABLE 55 NORTH AMERICA BIO MACROMOLECULES IN EXOSOME THERAPEUTIC MARKET, BY TRANSPORTING CAPACITY, 2017-2026 (USD MILLION)

TABLE 56 NORTH AMERICA EXOSOME THERAPEUTIC MARKET, BY APPLICATION, 2017-2026 (USD MILLION)

TABLE 57 NORTH AMERICA ONCOLOGY IN EXOSOME THERAPEUTIC MARKET, BY APPLICATION, 2017-2026 (USD MILLION)

TABLE 58 NORTH AMERICA NEUROLOGY IN EXOSOME THERAPEUTIC MARKET, BY APPLICATION, 2017-2026 (USD MILLION)

TABLE 59 NORTH AMERICA EXOSOME THERAPEUTIC MARKET, BY ROUTE OF ADMINISTRATION, 2017-2026 (USD MILLION)

TABLE 60 NORTH AMERICA EXOSOME THERAPEUTIC MARKET, BY END USER, 2017-2026 (USD MILLION)

TABLE 61 U.S. EXOSOME THERAPEUTIC MARKET, BY TYPE, 2017-2026 (USD MILLION)

TABLE 62 U.S. NATURAL EXOSOMES IN EXOSOME THERAPEUTIC MARKET, BY TYPE, 2017-2026 (USD MILLION)

TABLE 63 U.S. EXOSOME THERAPEUTIC MARKET, BY SOURCE, 2017-2026 (USD MILLION)

TABLE 64 U.S. BLOOD IN EXOSOME THERAPEUTIC MARKET, BY SOURCE, 2017-2026 (USD MILLION)

TABLE 65 U.S. BODY FLUIDS IN EXOSOME THERAPEUTIC MARKET, BY SOURCE, 2017-2026 (USD MILLION)

TABLE 66 U.S. EXOSOME THERAPEUTIC MARKET, BY THERAPY, 2017-2026 (USD MILLION)

TABLE 67 U.S. EXOSOME THERAPEUTIC MARKET, BY TRANSPORTING CAPACITY, 2017-2026 (USD MILLION)

TABLE 68 U.S. BIO MACROMOLECULES IN EXOSOME THERAPEUTIC MARKET, BY TRANSPORTING CAPACITY, 2017-2026 (USD MILLION)

TABLE 69 U.S. EXOSOME THERAPEUTIC MARKET, BY APPLICATION, 2017-2026 (USD MILLION)

TABLE 70 U.S. ONCOLOGY IN EXOSOME THERAPEUTIC MARKET, BY APPLICATION, 2017-2026 (USD MILLION)

TABLE 71 U.S. NEUROLOGY IN EXOSOME THERAPEUTIC MARKET, BY APPLICATION, 2017-2026 (USD MILLION)

TABLE 72 U.S. EXOSOME THERAPEUTIC MARKET, BY ROUTE OF ADMINISTRATION, 2017-2026 (USD MILLION)

TABLE 73 U.S. EXOSOME THERAPEUTIC MARKET, BY END USER, 2017-2026 (USD MILLION)

TABLE 74 MEXICO EXOSOME THERAPEUTIC MARKET, BY TYPE, 2017-2026 (USD MILLION)

TABLE 75 MEXICO NATURAL EXOSOMES IN EXOSOME THERAPEUTIC MARKET, BY TYPE, 2017-2026 (USD MILLION)

TABLE 76 MEXICO EXOSOME THERAPEUTIC MARKET, BY SOURCE, 2017-2026 (USD MILLION)

TABLE 77 MEXICO BLOOD IN EXOSOME THERAPEUTIC MARKET, BY SOURCE, 2017-2026 (USD MILLION)

TABLE 78 MEXICO BODY FLUIDS IN EXOSOME THERAPEUTIC MARKET, BY SOURCE, 2017-2026 (USD MILLION)

TABLE 79 MEXICO EXOSOME THERAPEUTIC MARKET, BY THERAPY, 2017-2026 (USD MILLION)

TABLE 80 MEXICO EXOSOME THERAPEUTIC MARKET, BY TRANSPORTING CAPACITY, 2017-2026 (USD MILLION)

TABLE 81 MEXICO BIO MACROMOLECULES IN EXOSOME THERAPEUTIC MARKET, BY TRANSPORTING CAPACITY, 2017-2026 (USD MILLION)

TABLE 82 MEXICO EXOSOME THERAPEUTIC MARKET, BY APPLICATION, 2017-2026 (USD MILLION)

TABLE 83 MEXICO ONCOLOGY IN EXOSOME THERAPEUTIC MARKET, BY APPLICATION, 2017-2026 (USD MILLION)

TABLE 84 MEXICO NEUROLOGY IN EXOSOME THERAPEUTIC MARKET, BY APPLICATION, 2017-2026 (USD MILLION)

TABLE 85 MEXICO EXOSOME THERAPEUTIC MARKET, BY ROUTE OF ADMINISTRATION, 2017-2026 (USD MILLION)

TABLE 86 MEXICO EXOSOME THERAPEUTIC MARKET, BY END USER, 2017-2026 (USD MILLION)